Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma Group (MREO) Total Current Liabilities: 2020-2025

Historic Total Current Liabilities for Mereo BioPharma Group (MREO) over the last 2 years, with Sep 2025 value amounting to $6.0 million.

  • Mereo BioPharma Group's Total Current Liabilities fell 57.66% to $6.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.0 million, marking a year-over-year decrease of 57.66%. This contributed to the annual value of $13.8 million for FY2024, which is 45.98% up from last year.
  • Per Mereo BioPharma Group's latest filing, its Total Current Liabilities stood at $6.0 million for Q3 2025, which was down 20.39% from $7.6 million recorded in Q2 2025.
  • In the past 5 years, Mereo BioPharma Group's Total Current Liabilities ranged from a high of $44.3 million in Q2 2022 and a low of $6.0 million during Q3 2025.
  • For the 3-year period, Mereo BioPharma Group's Total Current Liabilities averaged around $10.6 million, with its median value being $10.2 million (2023).
  • In the last 5 years, Mereo BioPharma Group's Total Current Liabilities skyrocketed by 221.32% in 2022 and then tumbled by 57.66% in 2025.
  • Quarterly analysis of 5 years shows Mereo BioPharma Group's Total Current Liabilities stood at $16.9 million in 2021, then soared by 221.32% to $44.3 million in 2022, then reached $9.5 million in 2023, then surged by 45.98% to $13.8 million in 2024, then plummeted by 57.66% to $6.0 million in 2025.
  • Its last three reported values are $6.0 million in Q3 2025, $7.6 million for Q2 2025, and $7.5 million during Q1 2025.